Vascular Biogenics Ltd. (Nasdaq: VBLT) reported positive interim results from a Phase 2 study of VB-111 in patients with recurring glioblasotoma. The stock price soared $1.63 to close at $7.22.
Vascular Biogenics reports positive interim data
March 25, 2015 at 16:40 PM EDT